Unicycive Therapeutics Announced It Has Entered Into A Securities Purchase Agreement With Certain Healthcare-focused Institutional Investors For The Sale Of 50,000 Shares Of Its Series B Convertible Preferred Stock At An Offering Price Of $1,000 Per Share
Unicycive Therapeutics宣佈已與某些以醫療保健爲重點的機構投資者簽訂證券購買協議，以每股1,000美元的發行價出售其B系列可轉換優先股的50,000股股票